
    <rss version="2.0" xmlns:itunes="http://www.itunes.com/dtds/podcast-1.0.dtd">
      <channel>
        <title>Articles tagged with Settlement from Medical Marketing and Media</title>
        <link>http://www.mmm-online.com/settlement/topic/8607/</link>
        <description>Articles tagged with Settlement from Medical Marketing and Media</description>
        <itunes:author>MMM</itunes:author>
        <itunes:subtitle></itunes:subtitle>
        <itunes:summary></itunes:summary>
        <itunes:owner>
            <itunes:name></itunes:name>
            <itunes:email>mmmsubs@haymarketmedia.com</itunes:email>
        </itunes:owner>
        <itunes:category text="BUSINESS">
            <itunes:category text="BUSINESS NEWS" /> 
        </itunes:category> 
        <itunes:image href='http://media.haymarketmedia.com/images/32/MMM_logo_28402_31022.gif'></itunes:image>
        <itunes:explicit>no</itunes:explicit>
  
        <item>
          <title>Business Briefs Merck, GSK, Novo, Walgreen, Epocrates, Doximity</title>
          <description>HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.</description>
          <link>http://www.mmm-online.com/business-briefs-merck-gsk-novo-walgreen-epocrates-doximity/article/292622/</link>
          <pubDate>Thu, 09 May 2013 14:56:06 GMT</pubDate>
          <itunes:summary>HPV vaccine price cut; Merck files new allergy med with FDA; GSK pursues online transparency; Walgreens ready for greater nurse autonomy; Epocrates ranks high among docs with tablets.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Novartis sued for alleged speaker-program abuse</title>
          <description>The Swiss drug maker is defending itself against two civil fraud lawsuits filed within a week of each other.</description>
          <link>http://www.mmm-online.com/novartis-sued-for-alleged-speaker-program-abuse/article/291064/</link>
          <pubDate>Mon, 29 Apr 2013 20:00:47 GMT</pubDate>
          <itunes:summary>The Swiss drug maker is defending itself against two civil fraud lawsuits filed within a week of each other.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Court could punt &quot;Pay for Delay&quot; back to Congress</title>
          <description>Eight members of the Supreme Court heard testimony in the case of FTC v. Actavis this morning, and the fate of so-called &quot;pay for delay&quot; settlements hangs in the balance.</description>
          <link>http://www.mmm-online.com/court-could-punt-pay-for-delay-back-to-congress/article/285987/</link>
          <pubDate>Mon, 25 Mar 2013 20:55:10 GMT</pubDate>
          <itunes:summary>Eight members of the Supreme Court heard testimony in the case of FTC v. Actavis this morning, and the fate of so-called &quot;pay for delay&quot; settlements hangs in the balance.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Business briefs: Gilead, Shire, The Medicines Co., HHS</title>
          <description>HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.</description>
          <link>http://www.mmm-online.com/business-briefs-gilead-shire-the-medicines-co-hhs/article/278976/</link>
          <pubDate>Mon, 04 Feb 2013 19:21:27 GMT</pubDate>
          <itunes:summary>HHS wants input for its TXT4Tots childhood advice program, Gilead releases some Hep. C clinical trial data, and Shire settles with the DOJ over disputed marketing practices.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>GSK&apos;s Connelly: We&apos;ve changed our ways (and please don&apos;t imprison execs)</title>
          <description>GlaxoSmithKline&apos;s Dierdre Connelly peeled back the curtain on the company&apos;s sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.</description>
          <link>http://www.mmm-online.com/gsks-connelly-weve-changed-our-ways-and-please-dont-imprison-execs/article/267037/</link>
          <pubDate>Mon, 05 Nov 2012 20:56:09 GMT</pubDate>
          <itunes:summary>GlaxoSmithKline&apos;s Dierdre Connelly peeled back the curtain on the company&apos;s sales force incentives revamp in a speech to the Pharmaceutical Regulatory and Compliance Congress, and pleaded for recognition that the industry had cleaned up the sketchy practices of the Blockbuster Era.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>For Forest, one Bystolic test down, six to go</title>
          <description>Forest Labs may have settled a patent challenge from generics maker Hetero, but the drugmaker has yet to come to terms with six others.</description>
          <link>http://www.mmm-online.com/for-forest-one-bystolic-test-down-six-to-go/article/265875/</link>
          <pubDate>Mon, 29 Oct 2012 17:10:29 GMT</pubDate>
          <itunes:summary>Forest Labs may have settled a patent challenge from generics maker Hetero, but the drugmaker has yet to come to terms with six others.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>J&amp;J sales up, but earnings wiped out by settlements, product liability and recall costs</title>
          <description>Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson &amp; Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip.</description>
          <link>http://www.mmm-online.com/jj-sales-up-but-earnings-wiped-out-by-settlements-product-liability-and-recall-costs/article/224544/</link>
          <pubDate>Tue, 24 Jan 2012 20:56:32 GMT</pubDate>
          <itunes:summary>Days after a $158 million settlement of charges that its Janssen unit fraudulently marketed Risperdal in Texas, Johnson &amp; Johnson forecast fourth-quarter net earnings of just $218 million due to settlement costs and the recall of its DePuy ASR artificial hip.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>Merck wraps up Vioxx litigation with feds, states: $1b in fines, new CIA</title>
          <description>Seven years after the biggest drug safety scandal since thalidomide was found to cause birth defects, Merck and the Justice Department announced a nearly $1 billion settlement of litigation over Vioxx, the Cox-2 pain drug found to cause strokes and heart attacks.</description>
          <link>http://www.mmm-online.com/merck-wraps-up-vioxx-litigation-with-feds-states-1b-in-fines-new-cia/article/217449/</link>
          <pubDate>Tue, 22 Nov 2011 23:18:50 GMT</pubDate>
          <itunes:summary>Seven years after the biggest drug safety scandal since thalidomide was found to cause birth defects, Merck and the Justice Department announced a nearly $1 billion settlement of litigation over Vioxx, the Cox-2 pain drug found to cause strokes and heart attacks.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>GSK hopes $3-bil. off-label settlement will end legal woes</title>
          <description>GlaxoSmithKline&apos;s deal to resolve multiple US investigations into its sales and marketing practices—one of the largest settlements by a pharma company—aims to patch up several long-running legal disputes.</description>
          <link>http://www.mmm-online.com/gsk-hopes-3-bil-off-label-settlement-will-end-legal-woes/article/216216/</link>
          <pubDate>Mon, 07 Nov 2011 22:07:21 GMT</pubDate>
          <itunes:summary>GlaxoSmithKline&apos;s deal to resolve multiple US investigations into its sales and marketing practices—one of the largest settlements by a pharma company—aims to patch up several long-running legal disputes.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
        <item>
          <title>GSK values drive flips rep bonus incentives</title>
          <description>The drug industry must move from a mindset that emphasizes compliance with regulations to one steeped in core values of integrity and transparency if it is to regain the public&apos;s trust, GSK&apos;s Dierdre Connelly said at a conference yesterday.</description>
          <link>http://www.mmm-online.com/gsk-values-drive-flips-rep-bonus-incentives/article/194976/</link>
          <pubDate>Tue, 25 Jan 2011 21:04:50 GMT</pubDate>
          <itunes:summary>The drug industry must move from a mindset that emphasizes compliance with regulations to one steeped in core values of integrity and transparency if it is to regain the public&apos;s trust, GSK&apos;s Dierdre Connelly said at a conference yesterday.</itunes:summary>
          <itunes:author>MMM</itunes:author>
          
        </item>
  
      </channel>
    </rss>  
  